Andrew Loblaw

10.5k total citations · 2 hit papers
237 papers, 6.6k citations indexed

About

Andrew Loblaw is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Surgery. According to data from OpenAlex, Andrew Loblaw has authored 237 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 187 papers in Pulmonary and Respiratory Medicine, 97 papers in Radiation and 45 papers in Surgery. Recurrent topics in Andrew Loblaw's work include Prostate Cancer Diagnosis and Treatment (160 papers), Prostate Cancer Treatment and Research (144 papers) and Advanced Radiotherapy Techniques (97 papers). Andrew Loblaw is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (160 papers), Prostate Cancer Treatment and Research (144 papers) and Advanced Radiotherapy Techniques (97 papers). Andrew Loblaw collaborates with scholars based in Canada, United States and Australia. Andrew Loblaw's co-authors include Liying Zhang, Laurence Klotz, Alexandre Mamedov, Robert K. Nam, Danny Vesprini, Adam Lam, Patrick Cheung, Suneil Jain, Gerard Morton and Hans T. Chung and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Andrew Loblaw

230 papers receiving 6.6k citations

Hit Papers

Long-Term Follow-Up of a ... 2009 2026 2014 2020 2014 2009 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
    2014 824 citations Laurence Klotz, Danny Vesprini et al. profile →
  2. Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
    2009 796 citations Laurence Klotz, Liying Zhang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Loblaw Canada 41 5.0k 1.6k 1.6k 1.3k 1.0k 237 6.6k
C.A. Reddy United States 52 5.9k 1.2× 1.5k 0.9× 2.3k 1.5× 1.2k 0.9× 1.3k 1.3× 340 9.3k
Tom Pickles Canada 47 4.5k 0.9× 950 0.6× 1.3k 0.9× 1.2k 0.9× 640 0.6× 196 6.1k
Juanita Crook Canada 51 5.6k 1.1× 1.9k 1.2× 3.1k 2.0× 1.0k 0.8× 1.5k 1.5× 278 8.3k
C.A. Lawton United States 34 5.2k 1.0× 831 0.5× 2.1k 1.4× 680 0.5× 819 0.8× 132 6.2k
Thomas M. Pisansky United States 51 7.2k 1.5× 2.3k 1.4× 2.8k 1.8× 1.8k 1.4× 1.3k 1.3× 215 9.8k
Miljenko V. Pilepich United States 47 6.3k 1.3× 1.6k 1.0× 1.9k 1.3× 1.2k 0.9× 720 0.7× 111 7.6k
Thomas Wiegel Germany 38 8.2k 1.6× 1.9k 1.2× 1.3k 0.8× 1.8k 1.4× 1.7k 1.7× 232 10.5k
Jay P. Ciezki United States 32 5.2k 1.0× 1.1k 0.7× 1.6k 1.0× 817 0.6× 636 0.6× 127 6.1k
Richard Cowan United Kingdom 40 2.4k 0.5× 1.0k 0.6× 1.3k 0.8× 1.0k 0.8× 776 0.8× 138 5.2k
Kathryn Winter United States 52 5.5k 1.1× 4.0k 2.4× 2.7k 1.7× 2.6k 2.0× 1.1k 1.1× 163 10.3k

Countries citing papers authored by Andrew Loblaw

Since Specialization
Citations

This map shows the geographic impact of Andrew Loblaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Loblaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Loblaw more than expected).

Fields of papers citing papers by Andrew Loblaw

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Loblaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Loblaw. The network helps show where Andrew Loblaw may publish in the future.

Co-authorship network of co-authors of Andrew Loblaw

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Loblaw. A scholar is included among the top collaborators of Andrew Loblaw based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Loblaw. Andrew Loblaw is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klotz, Laurence, et al.. (2025). Prognostic value of MR visibility/invisibility in men on Active Surveillance. Prostate Cancer and Prostatic Diseases. 28(4). 879–886. 2 indexed citations
2.
Withey, Samuel J., Douglas Brand, Andrew Loblaw, et al.. (2024). Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity. Clinical and Translational Radiation Oncology. 46. 100769–100769. 3 indexed citations
3.
Ong, Wee Loon, Melanie Davidson, Mark Ruschin, et al.. (2023). Urethra contouring on computed tomography urethrogram versus magnetic resonance imaging for stereotactic body radiotherapy in prostate cancer. Clinical and Translational Radiation Oncology. 45. 100722–100722. 2 indexed citations
4.
Moore-Palhares, Daniel, Ling Ho, Lin Lü, et al.. (2023). Clinical implementation of magnetic resonance imaging simulation for radiation oncology planning: 5 year experience. Radiation Oncology. 18(1). 27–27. 19 indexed citations
5.
Ong, Wee Loon & Andrew Loblaw. (2023). The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer—Quo Vadimus?. World Journal of Urology. 41(12). 3485–3491. 4 indexed citations
6.
Martin, Ting, Colton Ladbury, Maxwell Tran, et al.. (2023). Stereotactic Body Radiation Therapy: A Radiosurgery Society Guide to the Treatment of Localized Prostate Cancer Illustrated by Challenging Cases. Practical Radiation Oncology. 14(2). e117–e131. 6 indexed citations
7.
Song, Jiheon, Mark T. Corkum, Andrew Loblaw, et al.. (2023). 44 Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer. Radiotherapy and Oncology. 186. S22–S23.
8.
Flannigan, Ryan, Andrew Matthew, Fred Saad, et al.. (2022). An environmental scan of sexual health services for cancer survivors among Canadian institutions. Canadian Urological Association Journal. 17(2). 1 indexed citations
9.
Jiang, Naomi, Donald B. Fuller, Andrew Loblaw, et al.. (2021). Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. International Journal of Radiation Oncology*Biology*Physics. 110(3). 731–737. 40 indexed citations
10.
Musunuru, Hima Bindu, Patrick Cheung, Danny Vesprini, et al.. (2021). Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): Efficacy, toxicity and quality of life. Radiotherapy and Oncology. 161. 40–46. 10 indexed citations
11.
Wang, Hanzhi, Lucas C. Mendez, Gerard Morton, et al.. (2020). Immune cell profiling in Gleason 9 prostate cancer patients treated with brachytherapy versus external beam radiotherapy: An exploratory study. Radiotherapy and Oncology. 155. 80–85. 7 indexed citations
12.
Alayed, Yasir, Andrew Loblaw, Merrylee McGuffin, et al.. (2020). Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boost. Radiotherapy and Oncology. 154. 29–35. 18 indexed citations
13.
14.
Musunuru, Hima Bindu, Laura D’Alimonte, Melanie Davidson, et al.. (2018). Phase 1-2 Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients With High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of Life. International Journal of Radiation Oncology*Biology*Physics. 102(5). 1438–1447. 41 indexed citations
15.
Loblaw, Andrew, Patrick Cheung, Laura D’Alimonte, et al.. (2013). Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes. Radiotherapy and Oncology. 107(2). 153–158. 138 indexed citations
16.
Saad, Fred, Sébastien J. Hotte, Charles Catton, et al.. (2013). CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. Canadian Urological Association Journal. 7(7-8). 231–231. 15 indexed citations
17.
Sethukavalan, Perakaa, Patrick Cheung, Colin Tang, et al.. (2012). Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy.. PubMed. 19(2). 6165–9. 38 indexed citations
18.
Pang, Geordi, A Bani‐Hashemi, P Au, et al.. (2008). Megavoltage cone beam digital tomosynthesis (MV-CBDT) for image-guided radiotherapy: a clinical investigational system. Physics in Medicine and Biology. 53(4). 999–1013. 18 indexed citations
19.
Chow, Edward, Lori Davis, Tony Panzarella, et al.. (2005). Accuracy of survival prediction by palliative radiation oncologists. International Journal of Radiation Oncology*Biology*Physics. 61(3). 870–873. 121 indexed citations
20.
Chow, Edward, Jackson Wu, Andrew Loblaw, & Carlos A. Pérez. (2003). Radiotherapeutic approaches to metastatic disease. World Journal of Urology. 21(4). 229–242. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C.A. Reddy Breakdown of academic impact, for papers by Tom Pickles Breakdown of academic impact, for papers by Juanita Crook Breakdown of academic impact, for papers by C.A. Lawton Breakdown of academic impact, for papers by Thomas M. Pisansky Breakdown of academic impact, for papers by Miljenko V. Pilepich Breakdown of academic impact, for papers by Thomas Wiegel Breakdown of academic impact, for papers by Jay P. Ciezki Breakdown of academic impact, for papers by Richard Cowan Breakdown of academic impact, for papers by Kathryn Winter
Rankless by CCL
2026